AxoGen (NASDAQ:AXGN) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• AxoGen (NASDAQ: AXGN) has received a "sell (D-)" rating from Weiss Ratings, indicating concerns about the company's stock performance.
• Investors maintain a mixed outlook on AxoGen, with four analysts rating the stock as "buy" and an average consensus target price of $25.75.
• AxoGen stock traded at $18.17 recently, showing a significant difference from its 12-month high of $21.00 and low of $9.22.

AxoGen (NASDAQ:AXGN - Get Free Report)'s stock had its "sell (d-)" rating restated by research analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

A number of other research analysts also recently weighed in on AXGN. HC Wainwright began coverage on shares of AxoGen in a research report on Tuesday, September 30th. They set a "buy" rating and a $25.00 price objective on the stock. Wall Street Zen upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $25.75.

AxoGen Stock Performance

AxoGen stock traded up $0.12 during midday trading on Friday, reaching $18.17. 485,739 shares of the company traded hands, compared to its average volume of 829,808. The firm has a market capitalization of $836.00 million, a price-to-earnings ratio of -181.68 and a beta of 1.04. The business has a 50 day moving average of $16.56 and a two-hundred day moving average of $14.07. AxoGen has a 12 month low of $9.22 and a 12 month high of $21.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.14 and a quick ratio of 2.67.

Insider Activity

In other news, Director William P. Mr. Burke sold 1,457 shares of the stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $18.02, for a total value of $26,255.14. Following the completion of the sale, the director directly owned 100 shares of the company's stock, valued at $1,802. This represents a 93.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 35,521 shares of company stock valued at $642,219 over the last three months. Corporate insiders own 2.78% of the company's stock.

Hedge Funds Weigh In On AxoGen

Several institutional investors have recently bought and sold shares of AXGN. First Light Asset Management LLC lifted its position in AxoGen by 1.2% during the second quarter. First Light Asset Management LLC now owns 4,529,243 shares of the medical equipment provider's stock valued at $49,142,000 after purchasing an additional 55,028 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AxoGen by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 2,538,607 shares of the medical equipment provider's stock worth $46,964,000 after buying an additional 112,679 shares during the last quarter. Balyasny Asset Management L.P. boosted its stake in AxoGen by 183.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider's stock worth $20,953,000 after purchasing an additional 1,250,968 shares in the last quarter. Soleus Capital Management L.P. boosted its stake in AxoGen by 0.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,459,395 shares of the medical equipment provider's stock worth $15,834,000 after purchasing an additional 13,278 shares in the last quarter. Finally, Wasatch Advisors LP lifted its stake in AxoGen by 85.1% during the 2nd quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider's stock valued at $15,557,000 after acquiring an additional 659,149 shares during the period. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.